Novo Nordisk to Acquire Catalent for $16.5 Billion
Novo Nordisk, a leading pharmaceutical company, has recently announced its agreement to acquire Catalent for a staggering $16.5 billion in cash. This news has sent Catalent stock soaring by 9%…
Navidea Biopharmaceuticals Faces Potential Delisting from NYSE American Exchange
Navidea Biopharmaceuticals (NASDAQ: NAVB) has experienced a significant drop in its shares, with prices falling by 16% to 8 cents. The company has been grappling with the possibility of delisting…